The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2011Multimodal MRI Markers for Parkinson's Disease
Objective/Rationale:
A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson’s disease (PD) would improve diagnosis... -
MJFF Research Grant, 2011Glyt1 Inhibitors Promote Dopaminergic Striatal Sprouting
Objective/Rationale:
An important goal in Parkinson’s disease therapy is to reverse the loss of the dopaminergic neurons of the striatum. We have found that compounds that act as glycine uptake... -
MJFF Research Grant, 2011Ghrelin Concentrations in CSF and Corresponding Serum Samples in PD Patients and Controls
Objective/Rationale:
The aim of this study is to establish a valid method for measuring ghrelin concentrations in human cerebrospinal fluid samples. Ghrelin is an appetite-stimulating hormone with... -
Rapid Response Innovation Awards, 2011Psychological Stress as a Risk Factor for Parkinson's Disease
Objective/Rationale:
All persons experience psychological stress. In fact, its pervasiveness is the primary cause of countless diseases. Although the impact of psychological stress on Parkinson’s... -
Rapid Response Innovation Awards, 2011Assessment of AAV Transduction with Wildtype and Constitutively Active p70S6K to Induce Axon Re-Growth in Dopamine Neurons
Objective/Rationale:
Available treatments for PD offer relief of symptoms, but none are able to restore the neural structures that have degenerated. Neuroscientists have long believed that surviving... -
Rapid Response Innovation Awards, 2011Xenon Neuroprotection in a Pre-clinical Parkinson's Model
Objective/Rationale:
Xenon is an anesthetic gas known to have an excellent safety profile. Recent research suggests that xenon administered at subanesthetic concentrations is neuroprotective in acute...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.